We thank Dr. Shubhakaran for his positive feedback on our article.1 Indeed, optical coherence tomography (OCT) is an interesting tool for imaging demyelinating CNS disorders. OCT enables clinicians to detect symptomatic optic nerve lesion at distance from the clinical episode, to detect asymptomatic optic nerve lesion(s) in clinically isolated syndrome (CIS),1 and relapsing-remitting multiple sclerosis (MS),2 and it may be of help to differentiate MS and neuromyelitis optica spectrum disorders.3 If the duration of OCT and 3D-DIR sequence (6 minutes) remains quite close, it is true that accessibility to 3T-MRI scanner and spectral-domain (SD)-OCT are not equal all over the world. Symptomatic (30%) and asymptomatic (30%) optic nerve involvement is frequent at the earliest clinical stage of MS,4 but the optic nerve is still not part of MS diagnosis criteria. Considering optic nerve involvement could be useful for demonstrating dissemination in space (fifth typical location) and time (new lesion). In addition, optic nerve involvement at CIS stage was found significantly associated with the presence of asymptomatic gadolinium-enhanced lesion.5 As with others, we are convinced by the necessity of optic nerve inclusion in the next version of MS diagnosis criteria. SD-OCT—which is more accessible than MRI—will improve diagnosis workup, management, and follow-up of patients affected by CNS demyelinating disorders.